BRISTOL-MYERS SQUIBB COMPANY (BMY)

Healthcare · Pharmaceuticals · Price $66.95
Updated: Aug 28, 2026
Excellent Equity Returns — Healthcare
ROE of 46.69% — above the 20% excellent threshold Zyberno applies to Healthcare businesses.
ROE
46.69%
Return on Equity
ROIC
13.97%
Return on Invested Capital
ROA
10.28%
Return on Assets
Debt/Equity
2.49x
Leverage Ratio
Book Value/Share
$10.93
Equity Per Share

🧮 BMY ROE Calculation

ROE = Net Income / Shareholders' Equity
Net Income (TTM) $9.3B
Shareholders' Equity $22.3B
Total Debt $55.6B
Debt-to-Equity Ratio 2.49x
ROE (Return on Equity) 46.69%

Understanding ROE

Return on Equity (ROE) measures how efficiently a company generates profits from shareholders' equity. For BMY, the current ROE is 46.69%.

Why ROE Matters

Warren Buffett has called ROE one of his favorite metrics because it shows how well management uses shareholders' capital to generate returns. A company that consistently earns 15%+ ROE is typically a well-run business that creates value for shareholders.

High Leverage Warning

BMY's debt-to-equity ratio of 2.49x is elevated. High ROE combined with high debt can be a red flag — the company may be using financial leverage to boost returns, which increases risk. Compare to ROIC for a more complete picture.

ROE Benchmarks

Excellent: >20%

Exceptional returns on equity. Often indicates strong competitive advantages. Common in capital-light businesses.

Good: 15-20%

Above-average ROE. Buffett often looks for companies in this range or higher.

Average: 10-15%

Typical for most companies. Returns are reasonable but not exceptional.

Below Average: <10%

May indicate poor capital allocation or challenging business conditions.

The DuPont Analysis

ROE can be decomposed into three components using DuPont analysis:

ROE = Net Margin × Asset Turnover × Equity Multiplier

This breakdown reveals whether high ROE comes from high profitability (good), efficient asset use (good), or high leverage (potentially risky).

ROE vs ROIC: Which is Better?

ROIC: 13.97% →

ROIC measures returns on ALL capital. It's more comprehensive and less affected by leverage. Often considered the better quality metric.

ROE: 46.69%

ROE only measures returns on equity. Can be inflated by high debt. If ROE >> ROIC, the company uses significant leverage.

Owner Earnings: $11.9B →

Shows actual cash available to owners. Use alongside ROE and ROIC for complete analysis.

Net Income: $9.3B →

The numerator in ROE. Understanding net income trends helps explain ROE changes over time.

What to Look For

📊 Full BMY Stock Report

Intrinsic value, margin of safety, DCF valuation, and 250+ metrics.

🏆 BMY ROIC

Compare ROE to ROIC — the more comprehensive measure of capital efficiency.

💹 BMY P/E Ratio

Analyze valuation relative to earnings and understand market pricing.

👤 BMY Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 BMY Net Income

See the earnings that drive ROE calculations.

💵 BMY Free Cash Flow

Actual cash generation after capital expenditures.

View Full BMY Report Find More Quality Stocks
📊 Valuation Trilogy
Three interconnected metrics built on Owner Earnings
💎
Intrinsic Value
DCF Fair Value
$48.28
🛡️
Margin of Safety
Valuation Gap
-38.7%
🎯
Expected Return
Projected Annual
-13.5%
Click any metric for full methodology and detailed analysis

Summary: BMY Return on Equity

BRISTOL-MYERS SQUIBB COMPANY (BMY) has a ROE of 46.69%, which Zyberno classifies as excellent for a Healthcare company — above the 20% threshold Zyberno applies to healthcare companies where IP and regulatory advantages drive equity returns. Note: with a debt-to-equity of 2.49x, leverage is amplifying these returns — compare with ROIC (13.97%) for a leverage-neutral view. For complete financial analysis, view the full BMY stock report on Zyberno.

Frequently Asked Questions

What is BMY's current ROE?

BRISTOL-MYERS SQUIBB COMPANY's Return on Equity (ROE) is 46.69%, measured against the 20% excellent threshold Zyberno applies to Healthcare businesses. ROE measures the company's profitability relative to shareholders' equity.

Is BMY's ROE good?

BRISTOL-MYERS SQUIBB COMPANY (BMY) has a ROE of 46.69%, which Zyberno classifies as excellent for a Healthcare company — above the 20% threshold Zyberno applies to healthcare companies where IP and regulatory advantages drive equity returns. Note: with a debt-to-equity of 2.49x, leverage is amplifying these returns — compare with ROIC (13.97%) for a leverage-neutral view.

What is the difference between ROE and ROIC?

ROE measures returns on shareholder equity only, while ROIC measures returns on all invested capital (debt + equity). BMY's ROE is 46.69% vs ROIC of 13.97%. ROE can be inflated by high debt, making ROIC often a more reliable quality metric.

Can high ROE be misleading?

Yes, high ROE can be misleading if achieved through high debt. BMY's debt-to-equity ratio is 2.49x. Compare ROE to ROIC — if ROE is much higher than ROIC, the company uses significant leverage which adds risk.

📊 Full BMY Stock Report

See BMY's intrinsic value, margin of safety, DCF valuation, and complete financial analysis with 250+ metrics.

🏆 BMY ROIC

Compare to Return on Invested Capital — the most comprehensive measure of capital efficiency.

💹 BMY P/E Ratio

Analyze the price-to-earnings ratio and earnings yield as a valuation metric.

🎯 BMY Earnings Surprise (SUE)

See whether BMY is beating or missing its own earnings trend — Standardized Unexpected Earnings and post-earnings drift.

👤 BMY Owner Earnings

Warren Buffett's preferred measure of true economic earnings available to owners.

💰 BMY Net Income

See the bottom-line profit that drives return calculations.

📊 BMY EPS

Earnings per share — net income on a per-share basis.

View Full BMY Report Find More Quality Stocks
Scroll to Top